Monographie - Carfilzomib

Carfilzomib

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Kyprolis

Almanya, Amerika Birleşik Devletleri, Belçika, Büyük Britanya, İspanya, İsviçre, Meksika, Romanya

Kaynaklar : Carfilzomib

	Tip	Yayın
3348	Laboratuar	Carfilzomib (Kyprolis®) - Résumé des caractéristiques du produit Amgen 2016
3986	Dergi	Kim S, Krämer I. Physikalisch-chemische Stabilität von Carfilzomib (Kyprolis®) im Originalbehältnis nach Erstanbruch und in applikationsfertigen Zubereitungen. Krankenhauspharmazie 2017 ;38:377-82.
4045	Dergi	Sestak V, Roh J, Klepalova L, Kovarikova P. A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor. J Pharm Biomed Anal 2016 ;124:365-373
4047	Dergi	Kim S.H, Krämer I. Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period. J Oncol Pharm Practice 2017 ;25,2: 339-350